RAB1C, member RAS oncogene family (pseudogene)Genealiases: []
Q-omics provides the consensus-scored RAB1C profile across patient tissues and cancer cell-line models. RAB1C expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB1C is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, RAB1C RNA expression shows 13,834 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where RAB1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB1C survival associations across molecular data types. RAB1C RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB1C RNA expression–survival associations across cancer types. High RAB1C expression shows unfavorable associations in LGG, but favorable associations in KIRC, SKCM, KIRP, CHOL and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB1C RNA expression.
This table summarizes RAB1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAB1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB1C shows lower tumor expression in KIRP and THCA and higher tumor expression in HNSC, COAD, BRCA and LIHC. The HNSC box plot shows higher RAB1C RNA expression in tumor versus normal tissue (log2 FC = +0.209, t-test p < 0.001).
This table shows molecular features associated with RAB1C in patient tissues and cancer cell lines. In patient samples, RAB1C shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT.
